kesonotide (KS-c2) / Filamon - LARVOL DELTA

The innate immune mediator group IIA secreted phospholipase A2 modulates lipid droplet formation in prostate cancer cells. (PubMed, Front Cell Dev Biol) - "However, at high concentration of hGIIA, Kesonotide attenuated lipid metabolism by neutralizing perilipin remodelling and attenuating DGAT1 induction in knockout cells. Taken together, these findings identify a context-dependent hGIIA LD-remodelling program that is shaped by vimentin, implicating for the first time the hGIIA-vimentin axis in inflammatory cue-driven lipid metabolic rewiring in aggressive PCa."

Journal • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Metabolic Disorders • Oncology • Prostate Cancer • Solid Tumor • FASN • PLIN2 • VIM

ADVICE: Early Phase Study of Kesonotide in Participants With Solid Tumours (clinicaltrials.gov) - P1/2 | N=80 | Recruiting | Sponsor: Filamon LTD | Not yet recruiting ➔ Recruiting

Enrollment open • Brain Cancer • Breast Cancer • Genetic Disorders • Genito-urinary Cancer • Glioblastoma • Hormone Receptor Positive Breast Cancer • Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Prostate Cancer • Skin Cancer • Solid Tumor

ADVICE: Early Phase Study of Kesonotide in Participants With Solid Tumours (clinicaltrials.gov) - P1/2 | N=80 | Not yet recruiting | Sponsor: Filamon LTD | Initiation date: May 2025 ➔ Oct 2025

Trial initiation date • Brain Cancer • Breast Cancer • Genetic Disorders • Genito-urinary Cancer • Glioblastoma • Hormone Receptor Positive Breast Cancer • Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Prostate Cancer • Skin Cancer • Solid Tumor